FINWIRES · TerminalLIVE
FINWIRES

TPE:6589

3 stories mentioning TPE:6589Updated just now

Every FINWIRES story that references TPE:6589, newest first.

Asia

EirGenix Completes Capital Reduction Following RSA Write-Off

EirGenix (TPE:6589) completed the registration of its capital reduction following the write-off of 8,005 restricted stock award (RSA) shares on Monday, according to a Wednesday filing on the Taiwan Stock Exchange.Paid-in capital fell to NT$3.07 billion from NT$3.07 billion, while outstanding shares declined to 307.07 million from 307.08 million. Net worth per share remained unchanged at NT$25.38.The company expects 252 million common shares to be listed after the capital reduction and new issue, representing 82% of issued common shares.

TPE:6589
Asia

EirGenix Partner Secures EMA Nod for Breast Cancer Biosimilar Vial

EirGenix (TPE:6589) said the European Medicines Agency (EMA) approved a variation application submitted by its licensing partner Sandoz AG to add a 420 mg vial presentation for its trastuzumab biosimilar HERWENDA (EG12014).The biosimilar is indicated for the treatment of HER2-positive early and metastatic breast cancer, as well as metastatic gastric cancer, according to a Sunday Taiwan Exchange filing.EirGenix said the approval follows the launch of the 150 mg presentation in Slovakia and supports preparations for a broader commercial rollout across the European Union.

TPE:6589
Asia

Transcenta Secures 7 Million Yuan Milestone Payment Under EirGenix Bio-Platform Deal; Shares Fall 7%

Transcenta (HKG:6628) received a 7 million yuan milestone payment tied to the out-licensing of its highly intensified continuous bioprocessing platform, according to a Tuesday Hong Kong bourse filing.Shares of the biopharmaceutical company were down over 7% in late morning trade on Wednesday.The payment followed progress under the company's collaboration and non-exclusive licensing agreement with EirGenix (TPE:6589).

HKG:6628TPE:6589

Track with the FINWIRES app suite